CKD: cyclicals exposure, fragile earnings quality and limited upside at current price
Intrinsic value VND 20,433 vs market VND 20,000 — implied upside +2.2% (model confidence: very_low).
Business Overview
Công ty Cổ phần Cơ khí Đông Anh Licogi (CKD) is an industrial heavy-sector cyclical manufacturer listed on UPCOM with 31,000,000 shares outstanding. The company operates in heavy engineering / mechanical manufacturing within Vietnam's 'Công nghiệp nặng' category, supplying construction and industrial clients. As an UPCOM-listed firm partly controlled by a state-related parent (Tổng Công ty LICOGI holds c. 89.1%), CKD’s commercial decisions and dividend/payout profile are influenced by state ownership dynamics and SOE governance.
Investment Thesis
CKD’s valuation is close to the current market price: our EV/EBITDA mid-cycle model produces an intrinsic value of VND 20,433 per share versus a match price of VND 20,000, yielding only +2.2% upside with a recalibrated confidence flagged as very_low. On fundamentals, CKD shows pockets of operational profitability—ROE at 21.7% and net margin at 9.4%—and recent revenue growth has been modest (Revenue YoY +2.9% in 2025). However, several concerns undermine conviction: earnings quality is poor (score 20.7/100), forensic flags include a Beneish M-Score of -1.2079 (above the manipulation threshold of -1.78), an Altman Z-Score that places the company in the grey zone, and a Piotroski F-Score of 1, indicating weak operating/financial health. Leverage is elevated (Debt/Equity 1.66) and EV/EBITDA at 17.4 is materially above the sector median EV/EBITDA of 9.1, implying the company is priced for stronger earnings than currently evident.
Valuation Commentary
EV/EBITDA mid-cycle: we apply a mid-cycle EBITDA of VND 42,186,348,257 and a fair EV/EBITDA multiple of 21.59 (derived from the company's own historical distribution), calibrated isotonic to reconcile raw and calibrated outputs.
- Mid-cycle EBITDA: VND 42,186,348,257 (model input from own_median over 7 years).
- Fair EV/EBITDA multiple: 21.59 (own_history), compared with sector median EV/EBITDA 9.14.
- Observed EV/EBITDA: 17.4 (ratios_latest), implying current market pricing already reflects elevated expectations.
- Raw intrinsic value before calibration: VND 17,758 per share; isotonic calibration produced the final VND 20,433.
The tiny implied upside of +2.2% signals very limited valuation cushion versus execution and forensic risks. Confidence is very_low because of illiquidity, low earnings quality, and manipulation risk flagged by sanity checks; treat the intrinsic value as highly uncertain rather than precise.
Bull vs Bear
- High reported ROE of 21.7% suggests the company can generate shareholder returns when cycles are favorable.
- P/E of 5.2 and P/B of 1.0 imply the market is not demanding a premium and a recovery could re-rate multiples quickly.
- Stable revenue base: revenue rose from VND 1,255.1 bn in 2024 to VND 1,292.4 bn in 2025 (Revenue YoY +2.9%), providing a foundation for mid-cycle EBITDA assumptions.
- Dividend yield of 5.4% offers income support while awaiting operational improvement.
- Forensic and earnings-quality concerns: Beneish M-Score -1.2079 (in the 84th percentile among peers) and an Earnings Quality score of 20.7/100 elevate manipulation and measurement risk.
- High leverage (Debt/Equity 1.66) combined with an Altman Z-Score near the grey zone raises solvency concern if margins or cash conversion deteriorate.
- EV/EBITDA at 17.4 is well above sector median 9.1, meaning CKD must materially improve EBITDA to justify current valuation.
- Concentrated ownership: Tổng Công ty LICOGI holds ~89.1%, which reduces free float and may limit governance transparency and minority liquidity.
- Illiquidity: average two-week volume ~4,209 shares and sanity flags (illiquid) increase execution risk for investors wishing to enter/exit positions.
Sector Context
CKD sits in the heavy industry/cyclicals cluster where revenues track construction and capex cycles. Sector median EV/EBITDA is 9.14, substantially below CKD’s observed 17.4, suggesting peers trade at lower valuation multiples. Regulatory and macro context matters: SBV credit growth limits and state-directed project pipelines can materially affect orderbooks for heavy manufacturers. As a company with large SOE ownership, CKD may be subject to SOE dividend/payout mandates and related internal contracting that can influence reported profitability. Comparables in the sector show a wide dispersion: the top peers in our universe have large implied upsides (c. +40%), while some names show negative intrinsic re-ratings; CKD’s implied upside (+2.2%) is below the sector median upside of +5.6%.
Risk Factors
- Forensic/accounting risk: Beneish M-Score -1.2079 (> -1.78 threshold) and a YoY change in M-Score of +1.95 point to increased manipulation likelihood.
- Poor earnings quality: overall score 20.7/100 with cash conversion and receivables scoring 0, raising the risk that reported profits are not cash-backed.
- Leverage and solvency: Debt/Equity 1.66 and an Altman Z-Score of 1.88 (grey zone) increase bankruptcy risk if cash flows weaken.
- Liquidity & marketability: UPCOM listing, low avg. volume (~4,209 over 2 weeks) and very limited free float given 89.1% held by Tổng Công ty LICOGI.
- Valuation mismatch: EV/EBITDA (17.4) well above sector (9.1), requiring outsized EBITDA improvement to justify current prices.
- Concentration risk: top shareholder (state-related) controls c. 89.1%, which can constrain minority protections and strategic flexibility.
- Model confidence: valuation flagged as very_low and sanity flags include illiquid, low_earnings_quality, manipulation_risk — treat point estimates cautiously.
Catalysts
- Release of audited annual financials or external auditor commentary that resolves forensic concerns and improves earnings-quality perception.
- A clear orderbook or large contract announcement tied to state infrastructure projects that materially lifts mid-cycle EBITDA expectations.
- Reduction in leverage or asset sales that improve balance sheet metrics (Debt/Equity and Altman Z-Score).
- Improved free cash flow / operating cash conversion metrics reported in quarterly updates, addressing current cash-quality red flags.
Forensic Assessment
Forensic signals are the primary concern. Beneish M-Score of -1.2079 sits above the -1.78 threshold and is in the 84th percentile versus peers, indicating a non-trivial probability of aggressive accounting. The Earnings Quality score of 20.7/100 and Piotroski F-Score of 1 underline weak cash conversion and operational deterioration. Altman Z-Score of 1.88 puts the company in a cautionary grey zone for bankruptcy risk. There are no positive forensic signals in the dataset. Given these flags, reported earnings and free-cash-flow figures should be treated with skepticism until corroborated by improved cash metrics or external audit clarity.
Track Record
Our model has a historical track record of 12 years with a high nominal hit rate of 90.9% on directional calls; the average realized upside in those years was large (avg +176.0%). However, the model’s current confidence is very_low due to illiquidity and earnings-quality issues, and past performance should not be assumed to translate into reliable forward guidance for CKD specifically. Given the elevated forensic risk and concentrated ownership, historical model performance provides limited reassurance for this stock.
Written by a language model on 2026-08-10 from this page’s own model outputs and financial statements, and may quote figures from that date. Descriptive analysis, not investment advice — no buy, sell or hold recommendation is given or implied.